Hosted on MSN11mon
Novo’s Ozempic to face copycats as Chinese firm seeks biosimilar nod
Chinese drugmaker Hangzhou Jiuyuan Gene Engineering has sought regulatory clearance to market an off-patent version of Novo Nordisk’s (NVO) blockbuster diabetes therapy Ozempic, the company said ...
Yahoo Finance3mon
Hangzhou Jiuyuan Gene (2566.HK)
As global markets continue to reach new heights, with U.S. small-cap indices like the Russell 2000 achieving record levels, investors are increasingly looking towards smaller companies that may ...
Hosted on MSN11mon
China develops first biosimilar of globally popular weight loss drug Ozempic; Application submitted for approval
China’s Hangzhou Jiuyuan Gene Engineering has developed a biosimilar of Novo Nordisk’s popular diabetes drug Ozempic and applied for its approval. According to a statement by news agency ...